Made it into the pregnancy session in time for a really relevant talk by Annika Anderson - low transfer of CD20 molecules into mature breast milk (ie post colostrum) with infant dose <1%

In prospectively reported cases, no increased risk of spontaneous pregnancy loss, preterm birth, ectopic pregnancy. Rate of elective abortion in exposed pregnancies decreasing over time. Very few major congenital abnormalities - with a similar distribution to expected

Today at #ECTRIMS2022 with the poster on emulation of a clinical trial using real-world data from MSBase Registry. ECTRIMS

Reports of PML (The feared brain infection caused by the JC virus) with different disease modifying therapies for MS. Note rituximab-associated cases include "carry-over" PML in people who received Tysabri pubmed.ncbi.nlm.nih.gov/36283150/

If you are at #ECTRIMS2022 come and say hello to the UKMSR at our stand and find out how you could work with us.

#FrancescaBridge presenting our work demonstrating an increased risk of cervical pre-cancer in women exposed to high efficacy MS disease modifying therapy at #ECTRIMS2022 👏🏻👏🏻👏🏻

Great attendance and atmosphere at our MSBase members meeting last night. Seeing old friends and making new ones- all to improve outcomes research in #MS. Exciting to share our IT initiatives and first data from the launch of our myasthenia registry #MGBase.

Dr. Nicole Bou Rjeily starting a great presentation at ECTRIMS. Strong scientist and future neurologist! International Women in MS #iWiMS ECTRIMS

Collaboration with other #MS registries through #BigMS is critical to study long term disease trajectories in #progressiveMS. Well done Luigi Francesco Pontieri!

Excellent talk by @annalauralerede from at #ECTRIMS2022 presenting on the different ways MS can progress over time (using MS Register data) and how important online registers are for tracking disease long term 👍🏼

Chao Zhu representing MSBase Registry data ECTRIMS #DMT efficacy. Congratulations to all MSBase investigators involved!

Visiting the hard working team at the MSBase Registry booth at #ECTRIMS2022 thank you to Charlotte Sartori, Pam Farr, Rein Moore, and Dusko Stupar for their amazing work on the operations team making the magic happen 🙌🏻

Izanne Roos presenting a non-inferiority study of ocrelizumab and rituximab on behalf of the MSBase Registry and the Danish registry

Kalincik MSBase Registry study: Propensity-matched #progressive #MS patients treated with AHSCT or natalizumab. No difference on relapse rates and disability progression. #ECTRIMS2022

🌷Late breaking news at #ECTRIMS2022 I amsterdam Surprising or not? Propensity matched study of #HSCT versus #Natalizumab in #progressive #MS revealed no difference in efficacy. Early treatment best, applies to both💡

New published data @MonashCCS Alfred Research Alliance Helmut butzkueven MSBase Registry to support clinical decision making for patients with #MultipleSclerosis who need to switch #treatment to fully control their disease. Read more👇 monash.edu/medicine/news/…

Is HSCT really that good? This analysis at #ECTRIMS2022 (unrandomized) found HSCT is better than gilenya but similar in efficacy to ocrevus and tysabri (in relapses, disability progression), though improvement was more common with HSCT. ectrims2022.abstractserver.com/program/#/deta…

Festive greetings and a joyous Christmas from the MSBase Management team, to our amazing MSBase Ops Team, SLG committees, Board and valued Members - wishing you all a safe and happy holiday season.

📢🔥Take note! Data from the massive MSBase Registry dataset shows that secondary and primary progressive MS disease differ in disease onset and course. This is super important to consider when studying disease modifying therapies. bit.ly/41i7x0w Izanne

Fantastic catching up with friends &colleagues from the #BigMS data registries. Collectively, we manage ~300,000 patient records. “Harmonise the people, harmonise the data” Melinda Magyari Dana Horakova maria trojano Jiří Drahota Vukusic sandra MSBase Registry Jan Hillert and many more!